Amir Saberi is a bioengineer by training and holds a PhD in Cell and Developmental Biology from University of Illinois at Urbana-Champaign. He was a Postdoctoral Fellow at Johns Hopkins University from 2016 to 2018 where he studied induced pluripotent stem cells and gene editing. He then moved into biotech startups, scaling from bench scientist to operations leader for two cell and gene therapy companies, where he streamlined R&D workflows and managed teams through complex pre-clinical programs. In 2024, he founded Ambryon to improve therapeutic development workflows and democratize access to advanced biomanufacturing across academia and industry.
Three design principles separate successful AAV programs from those that fail: receptor-aware capsid
Discover strategies to reduce base editor size for AAV delivery in gene therapy. This insight explores
